Safety and effectiveness of the Vertex Pulmonary Embolectomy System in acute intermediate-risk pulmonary embolism: the SPIRARE II pivotal trial.
Sayfo S, Stępniewski J, et al. • EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology • 2026
The Vertex Pulmonary Embolectomy System met its prespecified safety and effectiveness endpoints in acute intermediate-risk PE, with a 2.4% 48-hour composite major adverse event rate and a mean RV/LV ratio reduction of 0.39.
Key Findings
Results
The 48-hour composite major adverse event (MAE) rate was 2.4% in 123 patients, meeting the prespecified safety performance goal.
3 of 123 patients experienced a composite MAE within 48 hours.
The one-sided p-value against the performance goal was <0.0001.
This was a co-primary endpoint in a prospective, single-arm, multicentre pivotal trial at 19 sites in the United States and Europe.
Results
The RV/LV diameter ratio, assessed by core laboratory, fell significantly from baseline to 48 hours, exceeding the prespecified effectiveness performance goal.
Mean RV/LV ratio decreased from 1.44±0.33 at baseline to 1.05±0.21 at 48 hours.
The mean reduction was 0.39±0.33 (p<0.0001 versus the performance goal).
RV/LV was measured by computed tomography angiography and was the second co-primary endpoint.
Methods
The study enrolled patients with acute intermediate-risk PE who were haemodynamically stable but had RV strain on imaging.
Eligibility: symptom onset ≤14 days, CT angiography RV/LV ratio >0.9, and systolic blood pressure ≥90 mmHg.
Total enrolled population was 123 patients.
The study was a prospective, single-arm, multicentre pivotal investigation (ClinicalTrials.gov NCT06576427).
Methods
Prespecified secondary haemodynamic endpoints were collected immediately before and after the procedure in all patients.
Secondary endpoints included mean pulmonary artery pressure, total pulmonary vascular resistance, and cardiac index.
The abstract does not report the numerical values of these measures.
The authors state that the system enabled consistent right ventricular unloading.
Conclusions
The authors conclude that Transforming Fixation (TFX) technology provides stable control and reliable vessel access in mechanical aspiration thrombectomy.
TFX separates the flexibility needed for safe navigation from the support needed for procedural control.
It is designed to address catheter stiffness and instability, which may limit access and prevent effective RV unloading in existing systems.
The authors report that it delivered 'precise, stable control with reliable vessel access, enabling consistent right ventricular unloading.'
What This Means
This study tested a catheter-based device, the Vertex Pulmonary Embolectomy System, that removes blood clots from the lungs' arteries in people with a pulmonary embolism. Clots like these can strain the right side of the heart. Existing devices can be stiff or unstable, which may make it harder to reach the clots and relieve that strain. The new device uses a design called Transforming Fixation, which aims to stay flexible while being steered but provide firm support once in position.
The trial enrolled 123 patients at 19 centers in the United States and Europe. All had a recent pulmonary embolism, stable blood pressure, and signs of right heart strain on CT scans. All received the device, with no comparison group. Only 3 patients (2.4%) had a serious complication within 48 hours, which met the study's pre-set safety target. The ratio of right to left heart chamber size, a marker of heart strain, improved from an average of 1.44 to 1.05 at 48 hours, which met the effectiveness goal.
This research suggests the device can be used safely and can reduce right heart strain in this patient group. Because the study had no control group, it cannot show how the device compares with other treatments such as blood thinners alone or other thrombectomy devices. The abstract also does not report longer-term outcomes or the numerical results for pressure and blood flow measures.
Sayfo S, Stępniewski J, Gallo V, Rossi J, Lang I, Ingrassia J, et al.. (2026). Safety and effectiveness of the Vertex Pulmonary Embolectomy System in acute intermediate-risk pulmonary embolism: the SPIRARE II pivotal trial.. EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology. https://doi.org/10.4244/EIJ-D-26-00454